A national analysis presented at the 2025 AHA Scientific Sessions found that patients with HIV hospitalized with cardiac implantable electronic device–related infective endocarditis had significantly lower...
A new longitudinal study published in the Journal of the American Academy of Dermatology evaluated more than a decade of data from adults living with HIV, revealing a steady decline in dermatologic disease...
A pilot randomized trial found that offering immediate pre-exposure prophylaxis (PrEP) initiation with a 28-day starter pack in the emergency department did not improve PrEP use or retention compared with...
Managing HIV today means balancing speed, precision, and prevention. From deciding when to start antiretroviral therapy (ART) to optimizing follow-up labs and ensuring vaccine and prophylaxis coverage,...
Results from a phase 2B randomized, double-blind, placebo-controlled trial suggest that semaglutide not only reduces inflammation and adiposity in people with HIV but may also provide a neurocognitive...
Excess visceral fat, rather than BMI alone, is a key driver of cardiovascular risk in people with HIV receiving antiretroviral therapy. The study authors presented their findings at the Conference on...
A new analysis found no difference in cardiovascular event rates between immediate and deferred antiretroviral therapy initiation among adults with HIV who had high CD4+ counts and low baseline...
Researchers tested the impact of four different remotely delivered interventions and observed promising effects on several key health outcomes in patients over the age of 50 living with HIV.
Researchers evaluated the safety and efficacy of dolutegravir plus lamivudine in treatment-naive individuals with HIV without baseline resistance testing.
